Certain types of cancer treatments, such as hormone therapy for breast cancer, may actually cause the CEA level to go up. This elevation does not accurately reflect the state of the disease.
The CEA test is not a screening test for cancer. It is not useful for detecting the presence of cancer. Many cancers do not produce an increased CEA level.
CEA levels may be one of the criteria for determining whether the patient will benefit from more expensive studies, such as CT scan or MRI.
Some noncancerous diseases, such as hepatitis, inflammatory bowel disease, pancreatitis, and obstructive pulmonary disease, may cause an elevated CEA level.
A patient with colorectal cancer is most commonly given the Carcinoembryonic Antigen (CEA) test to monitor disease progression and response to treatment.
In general, a higher CEA level predicts a more severe disease, one that is less likely to be curable.
A rising CEA level may be the first sign of cancer return, and may show up months before other studies or patient symptoms would raise concern.
Determination of the CEA level is a laboratory blood test. Obtaining a specimen of blood for the study takes only a few minutes. CEA testing should be covered by most insurance plans.
But some benign diseases and certain cancer treatments may produce an elevated CEA test. Cigarette smoking will also cause the CEA level to be abnormally high.
CEA = carcinoma embryonic antigen
CEA Cesta was created in 1965.
CEA Technologies's population is 260.
Cea serin was created in 1997.